Menu

NEW YORK (GenomeWeb) – Qiagen and NeoGenomics said on Friday that they have inked a master service agreement designed to expedite the development and launch of companion diagnostics with pharmaceutical partners.

Under the terms of the partnership, Qiagen will provide investigational-use-only tests to NeoGenomics and other labs "enabling them to verify, set up, and run our companion diagnostics in clinical trials and in anticipation of regulatory approval," Qiagen CEO Peer Schatz said in a statement.